What is SYRE's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 7.91B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for SYRE?

P/E (TTM) is n/a and 52-week range is $17.65 to $110.17 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s SYRE figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for SYRE?

The company profile lists revenue (TTM) near $1M, net income (TTM) near $-27.26B, EPS (TTM) near $-2.32 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Spyre Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Waltham, Massachusetts, US, 86.8M shares outstanding, ISIN US00773J2024 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Spyre Therapeutics Inc

$SYRE

Health Care · Biotechnology

IR Run Scenarios

$85.69

+7.25%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. The company is headquartered in Waltham, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2016-04-07. Its pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, SPY230, SPY002, SPY001, and SPY120. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a preclinical-stage program designed to bind to Interleukin 23 (IL-23) and incorporates half-life extending modifications.

Employees

112

Website

spyre.com/

IPO

2016-04-07

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)